Sandoz Strikes Shionogi Partnership as Part of Pain Play
Executive Summary
By securing commercial rights to Shionogi’s Rizmoic drug for opioid-induced constipation, Sandoz is seeking to broaden its European pain treatments portfolio.
You may also be interested in...
Sandoz To Acquire Aspen’s Japanese Operations
Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.
Sandoz Breaks Off Digital Deal With Pear
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.